Fake news. My liver is great and I've been using it for seven years now. Hope this helps.
Ivermectin can cause hepatotoxicity, but it is generally rare and most often associated with off-label, high-dose, or prolonged use. Standard single-dose treatment (150–200 µg/kg) for parasitic infections like onchocerciasis or scabies is typically well tolerated, with only mild, transient elevations in liver enzymes (ALT/AST) reported in some cases and clinically apparent liver injury considered very rare.
Risk increases with long-term, high-dose, or off-label use, particularly during the COVID-19 pandemic when repeated or unsupervised dosing—sometimes with veterinary formulations—led to more reports of hepatocellular injury, cholestasis, and even acute liver failure. However, causality is often difficult to establish due to confounding factors such as co-administered hepatotoxic drugs (e.g., remdesivir), underlying liver disease, or COVID-19 itself.
Patients with pre-existing liver conditions (e.g., cirrhosis, chronic hepatitis) are at higher risk due to reduced hepatic reserve and altered drug metabolism.
Case reports confirm rare but severe outcomes, including biopsy-confirmed ivermectin-induced hepatitis after a single dose.
Animal and cell studies show mixed results: while one zebrafish and Lo2 cell study found ivermectin disrupted lipid metabolism and caused liver damage via the AMPK/PPAR-α pathway, others demonstrated hepatoprotective effects against methotrexate-induced liver fibrosis in rats.
Ivermectin can cause hepatotoxicity, but it is generally rare and most often associated with off-label, high-dose, or prolonged use. Standard single-dose treatment (150–200 µg/kg) for parasitic infections like onchocerciasis or scabies is typically well tolerated, with only mild, transient elevations in liver enzymes (ALT/AST) reported in some cases and clinically apparent liver injury considered very rare.
Risk increases with long-term, high-dose, or off-label use, particularly during the COVID-19 pandemic when repeated or unsupervised dosing—sometimes with veterinary formulations—led to more reports of hepatocellular injury, cholestasis, and even acute liver failure. However, causality is often difficult to establish due to confounding factors such as co-administered hepatotoxic drugs (e.g., remdesivir), underlying liver disease, or COVID-19 itself.
Patients with pre-existing liver conditions (e.g., cirrhosis, chronic hepatitis) are at higher risk due to reduced hepatic reserve and altered drug metabolism.
Case reports confirm rare but severe outcomes, including biopsy-confirmed ivermectin-induced hepatitis after a single dose.
Animal and cell studies show mixed results: while one zebrafish and Lo2 cell study found ivermectin disrupted lipid metabolism and caused liver damage via the AMPK/PPAR-α pathway, others demonstrated hepatoprotective effects against methotrexate-induced liver fibrosis in rats.